Cassava not alone in showing positive impact on cognition.
My prior post included the following: “The fundamentals of our story are in place, which is this is the first drug—to our knowledge—that can restore cognition,” said Cassava’s founder and chief executive Remi Barbier.
However, Annovis seems like it can make a similar claim to showing evidence of improving cognition:
Last month, Annovis Bio announced data from a phase II study on ANVS401, its lead drug candidate for the treatment of AD and Parkinson’s disease (PD). The data showed that patients treated for 25 days with ANVS401 achieved statistically significant cognitive improvement as measured by the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 11 (ADAS-Cog11) test, which is one of the most frequently used tests to measure impaired cognition in clinical studies for AD. The drug also demonstrated improvements in speed, coordination and motor function in PD patients. Overall, the data proved that ANVS401 is efficacious in both AD and PD.
Market Data 
Markets 
AI
